Healthcare provider profile · identity verified

Raul E Gaona

Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1649259920

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Raul E Gaona received $352.19 in general payments during 2025 across 4 reported records.

Bayer Healthcare Pharmaceuticals Inc. accounted for 69.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic.

Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Kerendia by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$352.19

4 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Bayer Healthcare Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$244.74	69.5%	2	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$107.45	30.5%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$352.19	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Kerendia Normalized: kerendia	Drug	Bayer Healthcare Pharmaceuticals Inc.	$244.74	2	2025
Source payment records 2025-10-17 · Bayer Healthcare Pharmaceuticals Inc. · $119.76 · Open Payments source 2025-11-12 · Bayer Healthcare Pharmaceuticals Inc. · $124.98 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$58.16	1	2025
Source payment records 2025-10-24 · Novo Nordisk Inc · $58.16 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$49.29	1	2025
Source payment records 2025-10-23 · Novo Nordisk Inc · $49.29 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Kerendia kerendia	2025	Kerendia	2024	61	exact normalized	Medicare Part D
Ozempic ozempic	2025	Ozempic	2024	364	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	Kerendia open payments reported associated product	CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663	Kerendia · 2024 Exact normalized brand match · 1 Part D row	61	19
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	364	65
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	968	294
Levothyroxine Sodium	Levothyroxine Sodium	599	158
Atorvastatin Calcium	Atorvastatin Calcium	499	152
Ezetimibe	Ezetimibe	445	139
Amlodipine Besylate	Amlodipine Besylate	438	135
Gabapentin	Gabapentin	373	114
Ozempic	Semaglutide	364	65
Losartan Potassium	Losartan Potassium	346	103
Metformin Hcl	Metformin Hcl	309	97
Fluticasone Propionate	Fluticasone Propionate	305	120
Omeprazole	Omeprazole	254	85
Lisinopril	Lisinopril	248	77
Trazodone Hcl	Trazodone Hcl	248	85
Metoprolol Succinate	Metoprolol Succinate	225	78
Tramadol Hcl	Tramadol Hcl	211	49
Famotidine	Famotidine	206	70
Pioglitazone Hcl	Pioglitazone Hcl	202	71
Tamsulosin Hcl	Tamsulosin Hcl	202	71
Montelukast Sodium	Montelukast Sodium	191	71
Trulicity	Dulaglutide	189	36
Valsartan	Valsartan	180	58
Sertraline Hcl	Sertraline Hcl	173	61
Furosemide	Furosemide	170	55
Metoprolol Tartrate	Metoprolol Tartrate	163	52
Albuterol Sulfate Hfa	Albuterol Sulfate	159	49
Baclofen	Baclofen	157	55
Pantoprazole Sodium	Pantoprazole Sodium	150	52
Clopidogrel	Clopidogrel Bisulfate	138	38
Donepezil Hcl	Donepezil Hcl	136	44
Pravastatin Sodium	Pravastatin Sodium	129	38
Carvedilol	Carvedilol	127	46
Jardiance	Empagliflozin	124	37
Farxiga	Dapagliflozin Propanediol	115	38
Metformin Hcl Er	Metformin Hcl	111	38
Telmisartan	Telmisartan	108	33
Eliquis	Apixaban	103	29
Mounjaro	Tirzepatide	87	16
Clonazepam	Clonazepam	84	18
Escitalopram Oxalate	Escitalopram Oxalate	79	24
Prednisone	Prednisone	79	57
Spironolactone	Spironolactone	79	30
Vitamin D2	Ergocalciferol (Vitamin D2)	79	32
Alendronate Sodium	Alendronate Sodium	76	25
Allopurinol	Allopurinol	76	20
Nifedipine Er	Nifedipine	74	22
Soliqua 100-33	Insulin Glargine/Lixisenatide	65	22
Topiramate	Topiramate	65	19
Duloxetine Hcl	Duloxetine Hcl	62	23
Hydrochlorothiazide	Hydrochlorothiazide	61	23
Kerendia	Finerenone	61	19
Hydroxyzine Hcl	Hydroxyzine Hcl	60	22
Bupropion Xl	Bupropion Hcl	56	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	56	15
Pregabalin	Pregabalin	56	suppressed
Buspirone Hcl	Buspirone Hcl	55	22
Citalopram Hbr	Citalopram Hydrobromide	54	11
Mirtazapine	Mirtazapine	54	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	52	15
Finasteride	Finasteride	51	16
Benazepril Hcl	Benazepril Hcl	50	14
Synjardy Xr	Empagliflozin/Metformin Hcl	50	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	50	20
Venlafaxine Hcl Er	Venlafaxine Hcl	49	16
Ibuprofen	Ibuprofen	48	19
Ramipril	Ramipril	48	17
Synjardy	Empagliflozin/Metformin Hcl	47	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	44	25
Januvia	Sitagliptin Phosphate	43	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	43	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	11
Clotrimazole	Clotrimazole	42	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	14
Myrbetriq	Mirabegron	42	17
Linzess	Linaclotide	41	14
Alprazolam	Alprazolam	39	suppressed
Hydralazine Hcl	Hydralazine Hcl	39	18
Ondansetron Hcl	Ondansetron Hcl	39	17
Oxybutynin Chloride Er	Oxybutynin Chloride	39	13
Gemtesa	Vibegron	38	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	12
Potassium Chloride	Potassium Chloride	38	12
Propranolol Hcl	Propranolol Hcl	38	13
Fenofibrate	Fenofibrate	37	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	37	21
Zolpidem Tartrate	Zolpidem Tartrate	37	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	35	30
Ketoconazole	Ketoconazole	35	11
Levetiracetam	Levetiracetam	35	11
Lorazepam	Lorazepam	35	suppressed
Xarelto	Rivaroxaban	35	suppressed
Enalapril Maleate	Enalapril Maleate	34	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	34	suppressed
Glipizide	Glipizide	34	suppressed
Sucralfate	Sucralfate	34	suppressed
Lidocaine	Lidocaine	30	suppressed
Ventolin Hfa	Albuterol Sulfate	30	15
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Estradiol	Estradiol	28	12
Carbamazepine	Carbamazepine	27	suppressed
Glimepiride	Glimepiride	27	suppressed
Eplerenone	Eplerenone	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	12
Meclizine Hcl	Meclizine Hcl	26	14
Simvastatin	Simvastatin	26	suppressed
Torsemide	Torsemide	25	suppressed
Clobetasol Propionate	Clobetasol Propionate	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Fluconazole	Fluconazole	24	16
Memantine Hcl	Memantine Hcl	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	24	suppressed
Irbesartan	Irbesartan	23	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	23	23
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	22
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	15
Chlorthalidone	Chlorthalidone	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	21	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Atenolol	Atenolol	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Naloxone Hcl	Naloxone Hcl	20	suppressed
Repatha Sureclick	Evolocumab	20	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	18
Dicyclomine Hcl	Dicyclomine Hcl	19	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	19	suppressed
Rybelsus	Semaglutide	19	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Creon	Lipase/Protease/Amylase	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Sildenafil Citrate	Sildenafil Citrate	15	suppressed
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Colchicine	Colchicine	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Incontrol Pen Needle	Pen Needle, Diabetic	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Nitroglycerin Patch	Nitroglycerin	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Methylprednisolone	Methylprednisolone	12	12
Mometasone Furoate	Mometasone Furoate	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Xultophy 100-3.6	Insulin Degludec/Liraglutide	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Megestrol Acetate	Megestrol Acetate	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$352.19 · 4 records	Bayer Healthcare Pharmaceuticals Inc.	Kerendia, Ozempic, Wegovy	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Kerendia play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error